Enzyme News and Research

RSS

Researchers unveil new SARS-CoV-2 inhibitor that targets viral immune evasion

In a recent quest for an effective antiviral compound, UK researchers have purified a specific enzyme of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as nsp15 and optimized fluorescent biochemical endoribonuclease assays to screen a custom chemical library with over 5,000 commercial compounds. The study is currently available on the bioRxiv* preprint server.

11 Apr 2021

Previously approved drugs starting points for COVID-19 therapeutics

Researchers in the United States have identified several clinically approved compounds that could be repurposed for the treatment and prevention of coronavirus disease 2019 (COVID-19).

11 Apr 2021

New polypeptide could provide universal protection against coronaviruses

Researchers in the United States have developed an inhibitor of the spike protein found on the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that limits its formation in host human cells that would otherwise be the source of newly generated virions.

11 Apr 2021

Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants

A new monoclonal antibody targets a particular region of the RBD on the SARS-CoV-2. This region is usually not accessible to immune cells, which may be why it has broad neutralizing capabilities.

9 Apr 2021

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.

9 Apr 2021

Scientists develop microfluidic probe for free radical attack on live cells

Is there a way to chemically manipulate small, confined areas on cellular surfaces? Scientists have developed a microfluidic probe to send a flow of free radicals on live cells and track the outcome using fluorescence imaging.

9 Apr 2021

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Scientists from the University of Oxford and the University of Southampton report in the journal ACS Central Science that cells infected with the ChAdOx1 vaccine produce spike proteins on the cells similar to those produced by natural SARS-CoV-2 infection.

9 Apr 2021

IRB Barcelona researchers find the Achilles heel of some lung tumors

In cancer, personalized medicine takes advantage of the unique genetic changes in an individual tumor to find its vulnerabilities and fight it.

8 Apr 2021

Autoantibodies may contribute to severe COVID-19 and potential long-COVID-19 symptoms

New research in the USA and China. investigated how autoantibodies could mediate NETs during a COVID-19 infection. Extensive damage to the body from neutrophil extracellular traps (NETs) after infection may be contributing to thromboinflammation and the symptoms experienced by COVID-19 ‘long-haulers’.

8 Apr 2021

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

A recent report published in the New England Journal of Medicine has revealed that the COVID-19 vaccine developed by Moderna, Inc, USA, is capable of inducing robust and durable antibody responses for at least six months post-vaccination.

8 Apr 2021

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.

8 Apr 2021

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

A new preprint research paper posted to the bioRxiv server reports on the ability of a set of neutralizing mouse antibodies to protect mice against multiple lineages of SARS-CoV-2.

8 Apr 2021

Microrna-29 molecule controls brain maturation in mammals

A team led by scientists at the UNC School of Medicine identified a molecule called microRNA-29 as a powerful controller of brain maturation in mammals. Deleting microRNA-29 in mice caused problems very similar to those seen in autism, epilepsy, and other neurodevelopmental conditions.

8 Apr 2021

Landmark discovery may lead to safe, effective antiviral drugs against COVID-19

The COVID-19 vaccines currently rolling out are providing hope that the spread of the disease can be halted. But infection rates are still high, and for those who contract COVID-19, the search for effective treatments remains important.

8 Apr 2021

Parkinson's disease, type 2 diabetes, and cancer share the same pathway, shows study

When cells are stressed, chemical alarms go off, setting in motion a flurry of activity that protects the cell's most important players. During the rush, a protein called Parkin hurries to protect the mitochondria, the power stations that generate energy for the cell.

8 Apr 2021

The interaction between blood clotting and SARS-CoV-2 infection

Coagulopathy - a condition in which the blood's ability to clot is impaired, is recognized as a significant aspect of morbidity in COVID-19 patients. In a recent study, Prof Lewis Cantley and a team of researchers explored the role of coagulation factors in the SARS-CoV-2 infection. Their recent study is posted on the bioRxiv server.

7 Apr 2021

Mouse model provides new understanding about Folling Disease

In Norway, all newborn children are tested for 25 rare genetic diseases through the Newborn Screening program, and the most common of these is phenylketonuria (abbreviated to PKU), known as Folling Disease.

7 Apr 2021

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

A team of scientists from the University of California Santa Cruz, USA, recently identified a novel variant (B.1.x) of SARS-CoV-2 that might be circulating in at least 20 US states and six countries globally.

7 Apr 2021

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

A promising new study reports on the high neutralizing efficacy of a polyclonal swine antibody against SARS-CoV-2, the pathogen responsible for the novel COVID-19. By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.

7 Apr 2021

Which SARS-CoV-2 spike mutants can evade T cell immunity?

A new study reports the capability of a new variant of the virus to escape specific cellular immunity, while possessing a higher binding affinity to the host cell binding receptor, the angiotensin-converting enzyme 2 (ACE2).

7 Apr 2021

Enzyme News and Research

Researchers unveil new SARS-CoV-2 inhibitor that targets viral immune evasion

Previously approved drugs starting points for COVID-19 therapeutics

New polypeptide could provide universal protection against coronaviruses

Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

Scientists develop microfluidic probe for free radical attack on live cells

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

IRB Barcelona researchers find the Achilles heel of some lung tumors

Autoantibodies may contribute to severe COVID-19 and potential long-COVID-19 symptoms

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

Microrna-29 molecule controls brain maturation in mammals

Landmark discovery may lead to safe, effective antiviral drugs against COVID-19

Parkinson's disease, type 2 diabetes, and cancer share the same pathway, shows study

The interaction between blood clotting and SARS-CoV-2 infection

Mouse model provides new understanding about Folling Disease

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

Which SARS-CoV-2 spike mutants can evade T cell immunity?

Measuring Drug-Target Residence Times with Biochemical Assays eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo